Hopewest Grand Junction 2754 Compass Drive Ste 377, Grand Junction, CO, 81506 | |
(970) 241-2212 |
News Archive
More than 5,000 sociologists will convene in San Francisco this August to explore ideas and scientific research relating to economic inequality and many other topics, as part of the American Sociological Association's 109th Annual Meeting. This year's theme, "Hard Times: The Impact of Economic Inequality on Families and Individuals," draws attention to the many ways in which inequality reverberates throughout American society and the world.
Sanofi Pasteur, the vaccines division of Sanofi, announced today that the first lots of Fluzone (Influenza Virus Vaccine) for the 2013-2014 season have been released by the U.S. Food and Drug Administration for U.S. distribution and were shipped July 24.
arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody platform, announces it has signed a non-exclusive license agreement with BioWa Inc., the exclusive worldwide licensor of POTELLIGENT Technology.
Genetic sequencing technology is altering the way cancer is diagnosed and treated, but traditional specimen handling methods threaten to slow that progress.
› Verified 6 days ago
Name | Hopewest Grand Junction |
---|---|
Location | 2754 Compass Drive Ste 377, Grand Junction, Colorado |
Hospice ID | 061527 |
Category | Freestanding Hospice |
Ownership Type | Voluntary Non-profit - Private |
Profit Type | NON-PROFIT |
SSA county code | 380 |
News Archive
More than 5,000 sociologists will convene in San Francisco this August to explore ideas and scientific research relating to economic inequality and many other topics, as part of the American Sociological Association's 109th Annual Meeting. This year's theme, "Hard Times: The Impact of Economic Inequality on Families and Individuals," draws attention to the many ways in which inequality reverberates throughout American society and the world.
Sanofi Pasteur, the vaccines division of Sanofi, announced today that the first lots of Fluzone (Influenza Virus Vaccine) for the 2013-2014 season have been released by the U.S. Food and Drug Administration for U.S. distribution and were shipped July 24.
arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody platform, announces it has signed a non-exclusive license agreement with BioWa Inc., the exclusive worldwide licensor of POTELLIGENT Technology.
Genetic sequencing technology is altering the way cancer is diagnosed and treated, but traditional specimen handling methods threaten to slow that progress.
› Verified 6 days ago
NPI Number | 1427041227 |
Organization Name | Hopewest |
Address | 2754 Compass Dr Grand Junction, Colorado, 81506 |
Phone Number | (970)241-2212 |
News Archive
More than 5,000 sociologists will convene in San Francisco this August to explore ideas and scientific research relating to economic inequality and many other topics, as part of the American Sociological Association's 109th Annual Meeting. This year's theme, "Hard Times: The Impact of Economic Inequality on Families and Individuals," draws attention to the many ways in which inequality reverberates throughout American society and the world.
Sanofi Pasteur, the vaccines division of Sanofi, announced today that the first lots of Fluzone (Influenza Virus Vaccine) for the 2013-2014 season have been released by the U.S. Food and Drug Administration for U.S. distribution and were shipped July 24.
arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody platform, announces it has signed a non-exclusive license agreement with BioWa Inc., the exclusive worldwide licensor of POTELLIGENT Technology.
Genetic sequencing technology is altering the way cancer is diagnosed and treated, but traditional specimen handling methods threaten to slow that progress.
› Verified 6 days ago
Quality Measure | Provider Score | National Score |
---|---|---|
Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 98.9 | 98.3 |
Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 97.4 | 93.6 |
Patients who were checked for pain at the beginning of hospice care | 93.6 | 93.9 |
Patients who got a timely and thorough pain assessment when pain was identified as a problem | 72.4 | 77.7 |
Patients who were checked for shortness of breath at the beginning of hospice care | 99.9 | 97.3 |
Patients who got timely treatment for shortness of breath | 98.6 | 94.6 |
Patients taking opioid pain medication who were offered care for constipation | 94.7 | 93.3 |
News Archive
More than 5,000 sociologists will convene in San Francisco this August to explore ideas and scientific research relating to economic inequality and many other topics, as part of the American Sociological Association's 109th Annual Meeting. This year's theme, "Hard Times: The Impact of Economic Inequality on Families and Individuals," draws attention to the many ways in which inequality reverberates throughout American society and the world.
Sanofi Pasteur, the vaccines division of Sanofi, announced today that the first lots of Fluzone (Influenza Virus Vaccine) for the 2013-2014 season have been released by the U.S. Food and Drug Administration for U.S. distribution and were shipped July 24.
arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody platform, announces it has signed a non-exclusive license agreement with BioWa Inc., the exclusive worldwide licensor of POTELLIGENT Technology.
Genetic sequencing technology is altering the way cancer is diagnosed and treated, but traditional specimen handling methods threaten to slow that progress.
› Verified 6 days ago
Home Health Aides | 50 |
Counselors | 17 |
Medical Social Workers | 16 |
Physicians | 6 |
Registered Nurses | 128 |
Other Personnel | 124 |
Total Employees | 341 |
---|
News Archive
More than 5,000 sociologists will convene in San Francisco this August to explore ideas and scientific research relating to economic inequality and many other topics, as part of the American Sociological Association's 109th Annual Meeting. This year's theme, "Hard Times: The Impact of Economic Inequality on Families and Individuals," draws attention to the many ways in which inequality reverberates throughout American society and the world.
Sanofi Pasteur, the vaccines division of Sanofi, announced today that the first lots of Fluzone (Influenza Virus Vaccine) for the 2013-2014 season have been released by the U.S. Food and Drug Administration for U.S. distribution and were shipped July 24.
arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody platform, announces it has signed a non-exclusive license agreement with BioWa Inc., the exclusive worldwide licensor of POTELLIGENT Technology.
Genetic sequencing technology is altering the way cancer is diagnosed and treated, but traditional specimen handling methods threaten to slow that progress.
› Verified 6 days ago
Counselors | 1 |
Homemakers | 1 |
Physicians | 2 |
Others | 625 |
Total Volunteers | 629 |
---|
News Archive
More than 5,000 sociologists will convene in San Francisco this August to explore ideas and scientific research relating to economic inequality and many other topics, as part of the American Sociological Association's 109th Annual Meeting. This year's theme, "Hard Times: The Impact of Economic Inequality on Families and Individuals," draws attention to the many ways in which inequality reverberates throughout American society and the world.
Sanofi Pasteur, the vaccines division of Sanofi, announced today that the first lots of Fluzone (Influenza Virus Vaccine) for the 2013-2014 season have been released by the U.S. Food and Drug Administration for U.S. distribution and were shipped July 24.
arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody platform, announces it has signed a non-exclusive license agreement with BioWa Inc., the exclusive worldwide licensor of POTELLIGENT Technology.
Genetic sequencing technology is altering the way cancer is diagnosed and treated, but traditional specimen handling methods threaten to slow that progress.
› Verified 6 days ago
Hopewest Grand Junction Location: 2754 Compass Drive Ste 377, Grand Junction, Colorado, 81506 Phone: (970) 241-2212 |